BR55(VEGFR2靶向超声分子对比剂)在前列腺癌中的首次人体超声分子成像:安全性与可行性初步研究
这项首次人体0期探索性研究在24例活检证实前列腺癌并计划根治性前列腺切除术的患者中,用临床标准超声仪低机械指数成像评估BR55的安全性与可行性。0.03与0.05 mL/kg剂量可获给药后30分钟内对比增强图像,未见严重不良事件;组织病理证实的52个恶性病灶中26个(50%)在BR55成像中可见,采用改进方案的11例中28个恶性病灶可见19个(68%)。
要点
- BR55是靶向血管内皮生长因子受体2(VEGFR2)的超声分子对比剂,0.03与0.05 mL/kg剂量在给药后30分钟内可获得对比增强图像。
- 24例前列腺癌患者中未见严重不良事件或安全性监测数据的临床有意义改变。
- 组织病理证实的52个恶性病灶中26个(50%)在BR55成像中可见;改进方案组11例28个恶性病灶中19个(68%)可见。
核心结论
- BR55超声分子成像用临床标准技术可行,并显示出良好的安全性特征;前列腺癌患者可达到可检测的对比剂水平,为进一步临床试验开辟道路。
研究设计与样本
- 首次人体、0期、探索性初步研究,纳入24例活检证实前列腺癌并计划根治性前列腺切除术的患者,使用临床超声仪以低声功率成像。
- 安全性监测包括体格检查、血压与心率测量、心电图和血液采样。
- 作为首次人体研究,对比剂剂量与成像方案在入组过程中进行调整以改善可视化;成像数据与根治性前列腺切除术组织病理学对照分析检出率。
关键影像表现/征象
- BR55剂量0.03与0.05 mL/kg足以获得给药后长达30分钟的对比增强图像。
- 52个组织病理学确定的恶性病灶中26个(50%)在BR55成像中可见;改进方案组11例中28个恶性病灶中19个(68%)可见,9个(32%)未被识别。
局限性
- 作为首次人体研究,对比剂剂量与成像方案在入组过程中调整,前12例用于方案优化,后续12例采用改进方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: BR55, a vascular endothelial growth factor receptor 2 (VEGFR2)-specific ultrasound molecular contrast agent (MCA), has shown promising results in multiple preclinical models regarding cancer imaging. In this first-in-human, phase 0, exploratory study, we investigated the feasibility and safety of the MCA for the detection of prostate cancer (PCa) in men using clinical standard technology.
MATERIALS AND METHODS: Imaging with the MCA was performed in 24 patients with biopsy-proven PCa scheduled for radical prostatectomy using a clinical ultrasound scanner at low acoustic power. Safety monitoring was done by physical examination, blood pressure and heart rate measurements, electrocardiogram, and blood sampling. As first-in-human study, MCA dosing and imaging protocol were necessarily fine-tuned along the enrollment to improve visualization. Imaging data were correlated with radical prostatectomy histopathology to analyze the detection rate of ultrasound molecular imaging with the MCA.
RESULTS: Imaging with MCA doses of 0.03 and 0.05 mL/kg was adequate to obtain contrast enhancement images up to 30 minutes after administration. No serious adverse events or clinically meaningful changes in safety monitoring data were identified during or after administration. BR55 dosing and imaging were fine-tuned in the first 12 patients leading to 12 subsequent patients with an improved MCA dosing and imaging protocol. Twenty-three patients underwent radical prostatectomy. A total of 52 lesions were determined to be malignant by histopathology with 26 (50%) of them seen during BR55 imaging. In the 11 patients that were scanned with the improved protocol and underwent radical prostatectomy, a total of 28 malignant lesions were determined: 19 (68%) were seen during BR55 ultrasound molecular imaging, whereas 9 (32%) were not identified.
CONCLUSIONS: Ultrasound molecular imaging with BR55 is feasible with clinical standard technology and demonstrated a good safety profile. Detectable levels of the MCA can be reached in patients with PCa opening the way for further clinical trials.
引用
- Smeenge M, Tranquart F, Mannaerts CK, et al. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study. Invest Radiol. 2017. PMID: 28257340. doi:10.1097/RLI.0000000000000362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。